We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) to Expand Portfolio With Avida Biomed Acquisition
Read MoreHide Full Article
Agilent Technologies (A - Free Report) made an announcement to take over an early-stage life sciences company, Avida Biomed.
Avida Biomed develops high-performance target enrichment workflows to aid clinical researchers using next-generation sequencing (NGS) approaches in studying cancer.
The company offers genomics tools, which enable simultaneous genomic and DNA methylation profiling from a single sample, while maintaining sensitivity or specificity.
Avida Biomed’s chemistries and assays are compatible with Agilent’s automation platforms, Magnis and Bravo. The compatibility will enable efficient scaling of research experiments and routine sample testing.
The acquisition of Avida Biomed will highly complement Agilent’s SureSelect portfolio and NGS offerings. It will add strength to A’s portfolio of clinical research solutions.
With the takeover of Avida Biomed, Agilent aims to strengthen its presence in the booming clinical research and diagnostics markets.
On the back of Avida Biomed’s technology, Agilent will enable scientists working in precision medicine to develop approaches for a variety of clinical applications.
This will help Agilent gain momentum among clinical researchers and scientists, which, in turn, will drive its top-line growth in the days ahead.
Consequently, this will help the company win the confidence of the investors in the near and long terms.
Shares of Agilent have gained 2.1% in the past year against the Computer and Technology sector’s decline of 33.4%.
Growing Portfolio of Solutions
The recent announcement of acquiring Avida Biomed bodes well with Agilent’s growing initiatives toward expanding portfolio offerings to better serve its customers.
Apart from the latest move, Agilent released enhanced 8700 LDIR Chemical Imaging System for the analysis of microplastics in environmental samples.
The company also introduced the MassHunter BioConfirm 12.0 software, which supports data generated by Agilent high-resolution LC/MS assessing oligonucleotide purity and sequence confirmation required for biopharma research.
Agilent collaborated with APC Ltd. to combine their technologies and develop unique workflows to cater to the needs of customers in the biopharmaceutical and pharmaceutical industry.
We believe that the growing portfolio offerings will continue to help Agilent strengthen its presence in the life sciences, diagnostics and applied chemical markets.
Zacks Rank & Other Stocks to Consider
Currently, Agilent carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader Zacks Computer & Technology sector are Arista Networks (ANET - Free Report) , ASML Holding (ASML - Free Report) and Asure Software (ASUR - Free Report) . While Arista Networks and Asure Software currently sport a Zacks Rank #1 (Strong Buy), ASML carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arista Networks has lost 14.5% in the past year. The long-term earnings growth rate for ANET is projected at 17.5%.
ASML has moved 23.5% south in the past year. ASML’s long-term earnings growth rate is projected at 23.7%.
Asure Software has returned 34.1% in the past year. The long-term earnings growth rate for ASUR is projected at 23%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Agilent (A) to Expand Portfolio With Avida Biomed Acquisition
Agilent Technologies (A - Free Report) made an announcement to take over an early-stage life sciences company, Avida Biomed.
Avida Biomed develops high-performance target enrichment workflows to aid clinical researchers using next-generation sequencing (NGS) approaches in studying cancer.
The company offers genomics tools, which enable simultaneous genomic and DNA methylation profiling from a single sample, while maintaining sensitivity or specificity.
Avida Biomed’s chemistries and assays are compatible with Agilent’s automation platforms, Magnis and Bravo. The compatibility will enable efficient scaling of research experiments and routine sample testing.
Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote
Acquisition Benefits
The acquisition of Avida Biomed will highly complement Agilent’s SureSelect portfolio and NGS offerings. It will add strength to A’s portfolio of clinical research solutions.
With the takeover of Avida Biomed, Agilent aims to strengthen its presence in the booming clinical research and diagnostics markets.
On the back of Avida Biomed’s technology, Agilent will enable scientists working in precision medicine to develop approaches for a variety of clinical applications.
This will help Agilent gain momentum among clinical researchers and scientists, which, in turn, will drive its top-line growth in the days ahead.
Consequently, this will help the company win the confidence of the investors in the near and long terms.
Shares of Agilent have gained 2.1% in the past year against the Computer and Technology sector’s decline of 33.4%.
Growing Portfolio of Solutions
The recent announcement of acquiring Avida Biomed bodes well with Agilent’s growing initiatives toward expanding portfolio offerings to better serve its customers.
Apart from the latest move, Agilent released enhanced 8700 LDIR Chemical Imaging System for the analysis of microplastics in environmental samples.
The company also introduced the MassHunter BioConfirm 12.0 software, which supports data generated by Agilent high-resolution LC/MS assessing oligonucleotide purity and sequence confirmation required for biopharma research.
Agilent collaborated with APC Ltd. to combine their technologies and develop unique workflows to cater to the needs of customers in the biopharmaceutical and pharmaceutical industry.
We believe that the growing portfolio offerings will continue to help Agilent strengthen its presence in the life sciences, diagnostics and applied chemical markets.
Zacks Rank & Other Stocks to Consider
Currently, Agilent carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader Zacks Computer & Technology sector are Arista Networks (ANET - Free Report) , ASML Holding (ASML - Free Report) and Asure Software (ASUR - Free Report) . While Arista Networks and Asure Software currently sport a Zacks Rank #1 (Strong Buy), ASML carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arista Networks has lost 14.5% in the past year. The long-term earnings growth rate for ANET is projected at 17.5%.
ASML has moved 23.5% south in the past year. ASML’s long-term earnings growth rate is projected at 23.7%.
Asure Software has returned 34.1% in the past year. The long-term earnings growth rate for ASUR is projected at 23%.